A precision and reproducibilty assessment of liver fat measurement by chemical shift magnetic resonance scanning

Submission date	Recruitment status	Prospectively registered
28/04/2016	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2016	Completed	Results
Last Edited	Condition category	Individual participant data
16/03/2020	Digestive System	Record updated in last year

Plain English summary of protocol

Background & Aims

The gold standard technique for non-invasive measurement of liver fat has previously been Magnetic Resonance Spectroscopy. This tool is largely confined to the research setting as it requires high energy scanners which are resource intensive. Chemical Shift Magnetic Resonance (CS-MR) poses an alternative which is more applicable in the clinical setting as it can be used on conventional clinical Magnetic Resonance scanners. The accuracy with which CS-MR can repeatedly measure liver fat levels has not previously been assessed. This study aims to assess liver fat levels by using CS-MR in 10 patients on two occasions separated by a minimum of 24 hours. In this time, actual liver fat levels will not have changed. Statistical analysis will then be performed to determine the variation in results CS-MR produces between scans in the same patients. This will provide information on whether CS-MR can be used in studies and clinical practice to accurately detect changes in liver fat levels.

Who can participate?

Anybody over the age of 18 years old with a body mass index greater than 25.

What does the study involve?

Each participant is asked to attend Royal Blackburn Hospital on 2 occasions. During the first visit they are asked to provide a blood sample to assess liver function, circulating blood fat levels and sugar level control. The participants also have a short chemical shift magnetic resonance scan. On the second visit 4 weeks later another chemical shift magnetic resonance scan is performed.

What are the possible benefits?

There are no perceived benefits to participants. Travel expenses will be reimbursed.

When is the study starting? October 2015 to August 2017

Who is funding the study? Rosemere Cancer Foundation (UK) Where is the study running? East Lancashire Hospitals NHS Trust, Blackburn (UK)

Who is the main contact?

1. Mr Daren Subar (scientific) daren.subar@elht.nhs.uk

2. Ms Linda Gregson (public) linda.gregson@elht.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Mr Daren Subar

Contact details

Department of Hepatopancreatobiliary Surgery Royal Blackburn Hospital Haslingden Road Blackburn United Kingdom BB2 3HH +44 (0)1254 263555 daren.subar@elht.nhs.uk

Type(s)

Public

Contact name

Ms Linda Gregson

Contact details

Research and Development Department Royal Blackburn Hospital Haslingden Road Blackburn United Kingdom BB2 3HH 01254 263555 linda.gregson@elht.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study Protocol v2.0

Study information

Scientific Title

A precision and reproducibility assessment of intra-hepatic fat quantification by chemical shift magnetic resonance

Acronym

LiverPRIMEi

Study objectives

The aim of the study is to determine if chemical shift magentic resonance provides a precise and reproducible method of quantifiying intra-hepatic fat fraction using a clinical magentic resonace scanner.

Null Hypothesis:

1. There is no agreement between repeated quantifications of intra-hepatic fat fraction as measured by chemical shift magnetic resonance

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Single centre. Observational feasibility study.

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in electronic form. Please study team using public contact details provided.

Health condition(s) or problem(s) studied

Hepatic steatosis (fatty liver disease) and non-alcoholic fatty liver disease

Interventions

10 participants will undergo 2 chemical shift magnetic resonance scans using the clinical magnetic resonance scanner at Royal Blackburn Hospital.

These scans will be performed at least one day apart.

On visit 1, participants will also be asked to provide a blood sample for assessment of liver function, glycaemic control and lipid profile. Weight, height and hip-to-waist ratio will also be recorded. From this body mass index will be calculated.

No further blood samples will be acquired on the second visit.

Intra-person results will be statistically analysed for agreement using the Bland Altmann method with a priori variance levels of 0.2 deemed acceptable.

Intervention Type

Device

Primary outcome measure

Intrahepatic fat fraction as measured by 2 Chemical Shift Magnetic Resonance scans greater than 24 hours apart.

Secondary outcome measures

- 1. Indocyanine Green Plasma Disappearance Rate and Retention at 15 minutes, measured using a PULSiON Indocyanine Green Clearance Testing Device. This will be measured at visit 1 and 4 weeks later
- 2. BMI, Height, Weight and Hip to Waist ratio, measured at visit 1 and 2
- 3. Assessment of Liver function, Glycaemic control and Lipid profile, including Bilirubin, AST, ALT, ALP GGT, HbA1c, Random Glucose, Triglycerides and Cholesterol at visit 1.

Overall study start date

01/10/2015

Completion date

08/08/2017

Eligibility

Key inclusion criteria

- 1. Participants must be able to receive and understand verbal and written information regarding the study and give written, informed consent.
- 2. Participants should have features associated with intra-hepatic fat such as elevated BMI.
- 3. > 18 years old
- 4. Male or female

Participant type(s)

Patient

Age group

Adult

Lower age limit

Sex

Both

Target number of participants

10

Key exclusion criteria

- 1. Persons under 18 years of age
- 2. Conditions in which the supine position and breath holds required for MR scanning are not possible
- 3. Persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs
- 4. Persons with contraindications to MR imaging- presence of cardiac pacemaker/artificial heart valve/aneurysm clips/metallic fragments in eyes/cochlear implants
- 5. Pre-existing chronic liver pathology such as haemachromatosis, viral hepatitis or primary hepatic malignancy

Date of first enrolment

01/06/2016

Date of final enrolment

01/07/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

East Lancashire Hospitals NHS Trust

Royal Blackburn Hospital Haslingden Road Blackburn United Kingdom BB2 3HH

Sponsor information

Organisation

East Lancashire Hospitals NHS Trust

Sponsor details

Royal Blackburn Hospital Haslingden Road Blackburn England United Kingdom BB2 3HH +44(0)1254 263555 linda.gregson@elht.nhs.uk

Sponsor type

Hospital/treatment centre

Website

www.elht.nhs.uk

ROR

https://ror.org/002pa9318

Funder(s)

Funder type

Charity

Funder Name

Rosemere Cancer Foundation

Results and Publications

Publication and dissemination plan

We anticipate the results of this study to be published by peer-reviewed journals and presented at international surgical, anaesthetic and perioperative medicine conferences.

All patient-identifiable data will be anonymised before publication.

Intention to publish date

08/08/2018

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request